ARQT - Mizuho cuts Articus to neutral cites lower-than-expected prescriptions
2023-10-26 19:20:36 ET
More on Arcutis Biotherapeutics
- Arcutis Biotherapeutics, Inc. (ARQT) Q2 2023 Earnings Call Transcript
- Arcutis Biotherapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation
- Arcutis announces pricing of $100 million public offering
- Arcutis granted FDA label expansion for Zoryve psoriasis therapy
- Seeking Alpha’s Quant Rating on Arcutis Biotherapeutics
For further details see:
Mizuho cuts Articus to neutral, cites lower-than-expected prescriptions